The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it ...

Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.

At "Bio Japan 2025," Asia's largest pharmaceutical and bio exhibition, leading CDMO (Contract Development and Manufacturing ...

Daiichi Sankyo submits sNDA to Japan’s MHLW for Enhertu plus pertuzumab to treat patients with HER2 positive unresectable or recurrent breast cancer: Tokyo Wednesday, October 8, ...

My Green Lab strengthens governance through the addition of another senior AstraZeneca executive to its Board of Directors.

(Alliance News) - AstraZeneca PLC on Tuesday said its therapy for hypertension demonstrated positive results in a recent phase 3 trial, while its breast cancer therapy is put forward for review in ...

Doctors say they're seeing breast cancer survivors live longer amid an explosion of new treatment options. Dr. David Riseberg ...

Claudine Isaacs, MD: For this patient who's progressed after more than 12 months with an ESR1 mutation and HER2-low disease ...

October is Breast Cancer Awareness Month, a time to spotlight a disease that will affect hundreds of thousands of Americans ...

The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing ...

Dr. Liu: Over the past decade, breast cancer awareness and detection have improved through public education, better screening, and advanced imaging like 3D mammography. Genetic testing and ...

Findings from DESTINY-Breast11 showed T-DXd followed by THP demonstrated a statistically significant and clinically meaningful improvement in pCR rate vs ddAC-THP.